Scinovex
articleTop 1% cited

Wegener Granulomatosis: An Analysis of 158 Patients

Annals of Internal Medicine · 1992 · Vol. 116(6) · pp. 488–498
Gary S. HoffmanGail S. KerrRandi Y. LeavittClaire W. HallahanRobert S. LebovicsWilliam D. TravisMenachem RottemAnthony S. Fauci

Abstract

The course of Wegener granulomatosis has been dramatically improved by daily treatment with cyclophosphamide and glucocorticoids. Nonetheless, disease- and treatment-related morbidity is often profound. Alternative forms of therapy have not yet achieved the high rates of remission induction and successful maintenance that have been reported with daily cyclophosphamide treatment. Despite continued therapeutic success with cyclophosphamide, our long-term follow-up of patients with Wegener granulomatosis has led to increasing concerns about toxicity resulting from prolonged cyclophosphamide therapy and has encouraged investigation of other therapeutic regimens.

Vasculitis and related conditionsAutoimmune and Inflammatory DisordersSarcoidosis and Beryllium Toxicity ResearchMedicineDermatologyWegener granulomatosisGranulomatosis with polyangiitisVasculitisPathologyDisease

MeSH terms

AdolescentAdultAgedBiopsyChildCyclophosphamideDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMiddle AgedMorbidityOpportunistic InfectionsPrednisone
Citations
2,863
FWCI
63.57
field-weighted impact
References
42
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.